drugset / Trial / NCT01329991

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991 ↗

Phase 1 Completed 26 enrolled Plexxikon
RandomizedSingle-groupQuadruple-blindTreatment

Summary

PLX115-02 is a phase 1b study to assess how the study drug, PLX5622: 1. affects the body, 2. how the body affects PLX5622 3. the interaction of PLX5622 with Methotrexate and 4. the safety of PLX5622 in rheumatoid arthritis patients taking Methotrexate

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator PLX5622 Small molecule 200 mg Oral
Comparator PLX5622 Small molecule 400 mg Oral
Comparator PLX5622 Small molecule 800 mg Oral

Indications